Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 93 | 94 | 97 | 98 | 105 |
| Accounts receivable | 18 | 17 | -21 | N/A | N/A |
| Other Working Capital | 2,588 | -216 | -854 | -960 | 4,316 |
| Other Operating Activity | -9,350 | -5,366 | -5,720 | -6,984 | -9,253 |
| Operating Cash Flow | $-6,651 | $-5,471 | $-6,498 | $-7,846 | $-4,832 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | 0 | 0 | -6 | -32 |
| Investing Cash Flow | $-7 | $0 | $0 | $-6 | $-32 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -101 | -102 | -103 | -100 | -80 |
| Common Stock Issued | 4,239 | 5,475 | 5,993 | 3,439 | -158 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 65 |
| Financing Cash Flow | $4,138 | $5,373 | $5,890 | $3,339 | $-173 |
| Exchange Rate Effect | 246 | -579 | -31 | 857 | -215 |
| Beginning Cash Position | 14,626 | 15,303 | 15,942 | 19,598 | 24,850 |
| End Cash Position | 12,352 | 14,626 | 15,303 | 15,942 | 19,598 |
| Net Cash Flow | $-2,520 | $-98 | $-608 | $-4,513 | $-5,037 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,651 | -5,471 | -6,498 | -7,846 | -4,832 |
| Capital Expenditure | N/A | N/A | N/A | -6 | -32 |
| Free Cash Flow | -6,651 | -5,471 | -6,498 | -7,852 | -4,864 |